SECsense Logo

Biodexa Pharmaceuticals PLC: February 2025 Form 6-K Financial Report Insights

$BDRX
Form 6-K
Filed on: 2025-02-24
Source
Biodexa Pharmaceuticals PLC: February 2025 Form 6-K Financial Report Insights

Here are the key insights extracted from the provided section of the financial report (Form 6-K) for Biodexa Pharmaceuticals PLC:

  1. Company Information:
  • Name: Biodexa Pharmaceuticals PLC
  • Address: 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
  1. Filing Type:
  • This document is a Form 6-K, which is a report of foreign private issuer according to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
  1. Reporting Period:
  • The report is for the month of February 2025.
  1. Commission File Number:
  • 001-37652
  1. Annual Reports:
  • The company indicates that it will file annual reports under Form 20-F.
  1. Exhibit Information:
  • The document includes an exhibit:
    • Exhibit No. 99.1: Press Release dated February 24, 2025.
  1. Legal Disclaimer:
  • The information in Exhibit 99.1 is furnished and shall not be considered "filed" under the Securities Exchange Act of 1934 and is not subject to the liabilities of Section 18 of the Act.
  1. Signature:
  • The report is signed by Stephen Stamp, who holds the positions of Chief Executive Officer and Chief Financial Officer. The date of signing is February 24, 2025.

This report serves as an update for investors regarding company activities and any significant events that may impact their investment decisions. The inclusion of a press release suggests important news or developments were communicated by the company on that date.